CTKB · Cytek Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.13M | - | $52.29M | $45.60M | $41.46M | - | $51.50M | $46.62M | $44.86M | - |
| Cost of Revenue | $22.88M | - | $24.74M | $21.73M | $21.30M | - | $22.50M | $21.18M | $21.85M | - |
| Gross Profit | $21.25M | - | $27.55M | $23.87M | $20.16M | - | $29.00M | $25.44M | $23.01M | - |
| R&D | $9.60M | - | $8.96M | $8.83M | $9.72M | - | $9.88M | $10.00M | $9.80M | - |
| SG&A | $18.47M | - | $16.12M | $13.53M | $12.90M | - | $10.94M | $11.69M | $11.41M | - |
| Total Operating Expenses | $39.72M | - | $36.74M | $34.49M | $35.13M | - | $33.25M | $33.96M | $33.75M | - |
| D&A | $1.86M | - | $1.00M | $1.00M | $1.88M | - | $900.0K | $900.0K | $1.70M | - |
| Operating Income | ($18.46M) | - | ($9.19M) | ($10.62M) | ($14.97M) | - | ($4.25M) | ($8.53M) | ($10.73M) | - |
| Interest Expense | $262.0K | - | $494.0K | $414.0K | $441.0K | - | $119.0K | $134.0K | $441.0K | - |
| Income Tax | $1.49M | - | ($2.29M) | ($1.19M) | $136.0K | - | ($784.0K) | $3.25M | ($2.82M) | - |
| Net Income | ($18.87M) | - | ($5.48M) | ($5.58M) | ($6.17M) | - | $941.0K | ($10.43M) | ($6.17M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.67M | $90.85M | $93.28M | $75.47M | $95.30M | $98.72M | $162.27M | $177.89M | $168.79M | $167.30M |
| Accounts Receivable | $51.90M | $62.51M | $56.63M | $56.23M | $55.03M | $60.59M | $52.63M | $44.64M | $50.31M | $55.93M |
| Inventory | $49.79M | $48.43M | $51.65M | $49.49M | $45.35M | $43.89M | $46.80M | $50.07M | $54.74M | $60.88M |
| Accounts Payable | $6.74M | $6.41M | $7.63M | $6.85M | $6.25M | $5.53M | $5.39M | $3.19M | $3.73M | $3.03M |
| Current Assets | $379.30M | $392.00M | $388.49M | $382.82M | $380.50M | $396.45M | $390.19M | $384.08M | $388.65M | $392.06M |
| Total Assets | $449.11M | $461.54M | $494.92M | $493.32M | $482.60M | $499.50M | $491.23M | $483.73M | $492.07M | $494.46M |
| Current Liabilities | $80.94M | $77.80M | $75.21M | $73.27M | $67.69M | $67.66M | $62.80M | $52.38M | $55.57M | $56.23M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $121.47M | $119.80M | $116.35M | $115.76M | $102.97M | $103.76M | $105.76M | $94.60M | $99.45M | $101.39M |
| Stockholders' Equity | $327.64M | $341.74M | $378.57M | $377.56M | $379.62M | $395.74M | $385.46M | $389.12M | $392.61M | $393.06M |
| Retained Earnings | ($120.60M) | ($101.74M) | ($57.66M) | ($52.18M) | ($46.60M) | ($35.20M) | ($44.84M) | ($45.78M) | ($35.35M) | ($29.18M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.74M) | - | - | - | ($125.0K) | - | - | - | $3.96M | - |
| Investing Cash Flow | ($27.08M) | - | - | - | $9.45M | - | - | - | ($5.75M) | - |
| Financing Cash Flow | $3.98M | - | - | - | ($11.54M) | - | - | - | $1.61M | - |
| CapEx | $2.17M | - | - | - | $849.0K | - | - | - | $567.0K | - |
| Free Cash Flow | ($4.90M) | - | - | - | ($974.0K) | - | - | - | $3.39M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 48.2% | - | 52.7% | 52.3% | 48.6% | - | 56.3% | 54.6% | 51.3% | - |
| Operating margin | -41.8% | - | -17.6% | -23.3% | -36.1% | - | -8.2% | -18.3% | -23.9% | - |
| EBITDA margin | -37.6% | - | -15.7% | -21.1% | -31.6% | - | -6.5% | -16.4% | -20.1% | - |
| Net margin | -42.7% | - | -10.5% | -12.2% | -14.9% | - | 1.8% | -22.4% | -13.8% | - |
| Free cash flow margin | -11.1% | - | - | - | -2.3% | - | - | - | 7.6% | - |
| FCF / Net income | 0.26 | - | - | - | 0.16 | - | - | - | -0.55 | - |
| R&D / Revenue | 21.8% | - | 17.1% | 19.4% | 23.5% | - | 19.2% | 21.5% | 21.8% | - |
| SG&A / Revenue | 41.8% | - | 30.8% | 29.7% | 31.1% | - | 21.2% | 25.1% | 25.4% | - |
| Effective tax rate | - | - | - | - | - | - | -499.4% | - | - | - |
| Return on assets | -4.2% | - | -1.1% | -1.1% | -1.3% | - | 0.2% | -2.2% | -1.3% | - |
| Return on equity | -5.8% | - | -1.4% | -1.5% | -1.6% | - | 0.2% | -2.7% | -1.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.69 | 5.04 | 5.17 | 5.22 | 5.62 | 5.86 | 6.21 | 7.33 | 6.99 | 6.97 |
| Quick ratio | 4.07 | 4.42 | 4.48 | 4.55 | 4.95 | 5.21 | 5.47 | 6.38 | 6.01 | 5.89 |
| Cash ratio | 0.81 | 1.17 | 1.24 | 1.03 | 1.41 | 1.46 | 2.58 | 3.40 | 3.04 | 2.98 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -70.5x | - | -18.6x | -25.7x | -34.0x | - | -35.7x | -63.6x | -24.3x | - |
| Equity multiplier | 1.37 | 1.35 | 1.31 | 1.31 | 1.27 | 1.26 | 1.27 | 1.24 | 1.25 | 1.26 |
| Liabilities / Assets | 0.27 | 0.26 | 0.24 | 0.23 | 0.21 | 0.21 | 0.22 | 0.20 | 0.20 | 0.21 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.11 | 0.09 | 0.09 | - | 0.10 | 0.10 | 0.09 | - |
| Inventory turnover | 0.46 | - | 0.48 | 0.44 | 0.47 | - | 0.48 | 0.42 | 0.40 | - |
| Days sales outstanding | 429d | - | 395d | 450d | 484d | - | 373d | 350d | 409d | - |
| Days inventory outstanding | 794d | - | 762d | 831d | 777d | - | 759d | 863d | 915d | - |
| Days payable outstanding | 108d | - | 113d | 115d | 107d | - | 87d | 55d | 62d | - |
| Cash conversion cycle | 1116d | - | 1045d | 1166d | 1155d | - | 1045d | 1157d | 1262d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.7x | - | 1.2x | 1.1x | 1.4x | - | 1.9x | 1.9x | 2.2x | - |
| P / S | 12.7x | - | 8.5x | 9.5x | 12.4x | - | 14.3x | 15.7x | 19.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 6.5% | - | 1.5% | -2.2% | -7.6% | - | 7.3% | -6.2% | 21.0% | - |
| Revenue CAGR (3y) | 6.0% | - | 8.9% | 4.3% | 5.7% | - | 14.4% | 15.3% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 5.4% | - | -5.0% | -6.2% | -12.4% | - | 6.7% | -9.7% | 9.4% | - |
| Operating income growth (YoY) | -23.3% | - | -116.4% | -24.6% | -39.5% | - | 33.8% | 6.6% | 11.7% | - |
| Net income growth (YoY) | -205.8% | - | - | 46.5% | 0.0% | - | - | -137.8% | 9.4% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -403.5% | - | - | - | - | - | - | - | 44.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -13.7% | -13.6% | -1.8% | -3.0% | -3.3% | 0.7% | -7.2% | -8.3% | -7.3% | -7.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$201.49M totalReportable Segment$201.49M · 100.0%
Product / service
$201.49M totalProduct$144.23M · 71.6%
Service$57.26M · 28.4%
Geographic
$221.99M totalUS$95.25M · 42.9%
EMEA$55.88M · 25.2%
Asia Pacific$41.08M · 18.5%
CN$20.50M · 9.2%
Other$9.28M · 4.2%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Cytek Biosciences against the 5 most active filers in the same SIC group.